951 Silibinin Inhibits HCV Replication in Vitro

Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy

“…Regarding the first hypothesis, after a 12-week high-dose acarbose treatment (300 mg/d), our data in humans showed no effects on whole body insulin sensitivity, measured in the euglycemic clamp, and no changes in body weight [5]. Moreover, we observed …”

Intravenous Silibinin as ‘Rescue Treatment’ for On-Treatment Non-Responders to Pegylated Interferon/Ribavirin Combination Therapy

“…The antiviral effects of SIL were further reconfirmed by in vitro studies [13,14]. SIL inhibits the HCV NS5B polymerase activity directly [15] or by interfering with the binding of RNA to this enzyme [16]. Furthermore, the mechanisms of the antiviral action of SIL appear also to include blocking of virus entry, transmission and secretion [17].…”

Development and validation of two liquid chromatography–tandem mass spectrometry methods for the determination of silibinin and silibinin hemisuccinate in human plasma

“…On the one hand antiviral properties of silibinin are due to the host cellular level, mediated partly by induction of Stat 1 phosphorylation which activates intracellular IFN-induced pathways, and partly by IFN-independent mechanisms like for instance inhibition of the 5-lipoxygenase pathway [23]. On the other hand, data from virologic experiments prove that silibinin can directly inhibit HCV replication and functions [17,24], without selecting for resistance [25,26].…”